Synthesis and Evaluation of Peptidyl Vicinal Tricarbonyl Monohydrates as Inhibitors of Hydrolytic Enzymes

Harry H. Wasserman,^{*} David S. Ennis, Patricia L. Power, and Mitchell J. Ross

Department of Chemistry, Yale University, P.O. Box 6666, New Haven, Connecticut 06511

Bruce Gomes

Zeneca Pharmaceuticals Group, Department of Pharmacology, Wilmington, Delaware 19897

Received **May** *6,* **1993**

Summary: Peptidyl vicinal tricarbonyls, prepared from N-protected di- and tripeptides by reaction of the carboxylic acid residues with ylides followed by oxidation, have been shown to be potent inhibitors of serine proteases.

There has been considerable recent interest in small peptide substrate analogues which incorporate a strongly electron-deficient group at the site of the scissile amide unit and thereby act as potent inhibitors of hydrolytic enzymes such as α -chymotrypsin, human neutrophil elastase **(HNE),** and porcine pancreatic elastase (PPE).' The active carbonyls in groupings such as trifluoromethyl ketones (TFMK's),² α -diketones,³ and α -keto esters⁴ appear to be excellent acceptors for nucleophilic residues such as the serine hydroxyl or the thiol group of a cysteine unit in the enzyme molecule. Inhibition has been associated with the formation of a tetrahedral intermediate, which, in the case of serine, would be a hemiketal.¹

Among functional groups in which the electrophilic reactivity of the carbonyl group is greatly enhanced, the vicinal tricarbonyl unit stands out as one of the most powerful acceptors.⁵ The central (C_2) carbonyl group in this system is destabilized by dipolar effects in the ground state and forms a stable monohydrate which, in solution, is in equilibrium with the parent tricarbonyl group. The C_1 carbonyl, adjacent to the strongly electron-attracting C_2-C_3 α -dicarbonyl array, is also highly activated and readily forms hemiacetals in suitable environments as in $FK-506⁶$ and rapamycin.⁷ Reactions of these species with

38; R' = Cbz, **R2** = CH2Ph (66%) **3b; R'** = BOC, **R2** = H (64%) **3C;** R' = Cbz, **R2** = CH3 **(70%)**

donor molecules take place rapidly to form tetrahedral intermediates. In the setting of a small peptide aggregate, which is suitable for binding to the enzyme, one would expect such tricarbonyl derivatives to behave **as** potent enzyme inhibitors analogous to the corresponding TF- $MK's.²$

In our recent studies on the chemistry of vicinal tricarbonyl compounds, we have developed a mild, efficient reaction sequence for forming the 1,2,3-tricarbonyl aggregate from carboxylic acid precursors.8 This method, outlined below, has now been applied to the formation of tricarbonyl esters containing dipeptide and tripeptide residues.

Scheme I illustrates the general procedure by which the carboxylic acid (1 equiv)9 is coupled with an ylide **1** (1 equiv) in the presence of EDCI (1 equiv)¹⁰ and DMAP (catalytic) to form the keto phosphorane 2^{11} which can then be subsequently oxidized (1.5 equiv of Oxone in THF/ H20)12 to the hydrated tricarbonyl derivative **3.** Using peptidyl carboxylic acids **as** starting materials in this way,

⁽¹⁾ (a) Trainor, D. A. *Trends Pharmacol.* **Sci. 1987,8,303-307.** (b) Stein, M. M.; Wildonger, R. A.; Trainor, D. A.; Edwards, P. D.; Yee, Y. K.;Lewie., J.J.;Zottola,M.A.; **Williams,J.C.;Strimpler,A.M.InPeptides,** *Chemistry,Structure,andBiology* **(ProceedingsoftheEleventh** American Peptide Symposium); River, J. E., Marshall, G. R., Eds.; ESCOM: Leiden, 1990; pp 369–370. (c) Edwards, P. D.; Meyer, E. F., Jr.; Vijayalakshmi,
J.; Tuthill, P. A.; Andisik, D. A.; Gomes, B.; Strimpler, A. J. *Am. Chem.*
Soc. 1992, *114*, 1854–1863. (d) Stein, R. L.; Strimpler, A. M.; Edwards, P. D.; Lewis, J. J.; Mauger, R. C.; Schwartz, J. A.; **Stain,** M. M.; Trainor, D. A.; Wildonger, R. A.; Zottola, M. A. Biochemistry **1987,26,2682-2689.**

⁽²⁾ (a) Gelb, M. H.; Svaren, J. P.; Abeles, R. H. Biochemistry **1985,24, 1813-1817.** (b) Imperiali, B.; Abeles, R. H. Biochemistry **1986,25,3760- 3767.**

⁽³⁾ (a) Angelastro, M. R.; Mehdi, S.; Burkhart, J. P.; Peet, N. P.; Bey, P. *J.* Med. Chem. **1990, 33, 11-13.** (b) Mehdi, **S.;** Angelastro, M. R.; Burkhart, J. P.; Koehl, J. R.; Peet, N. P.; Bey, P. Biochem. Biophys. Res.

Commun. **1990,166, 595-600. (4)** (a) Peet, **N.** P.; Burkhart, J. P.; Angelastro, M. R.; Giroux, E. L.; Mehdi, S.; Bey, P.; Kolb, M.; Neises, B.; Schirlin, D. J. J. Med. *Chem.* **1990,33,394-407. (b)** Buckhart, **J.** P.; Peet, N. P.; Bey, P. *Tetrahedron Lett.* **1990,31, 1385-1388.**

Lett. 1990, 31, 1960–1966.
16. (5) (a) Wasserman, H. H.; Han, W. T. J. Am. Chem. Soc. 1985, 105,
1444–1446. (b) Wasserman, H. H.; Han, W. T. Tetrahedron Lett. 1984,
25, 3743–3746. (c) Wasserman, H. H.; Han, W. T. Tetrahedr **1984,25,3747-3750.** (d) Wasserman, H. H.; Amici, R.; Frechette, R.; van Duzer, J. H. *TetrahedronLett.* **1989,30,869-872.** (e) Wasserman, H. H.; Kuo, G-H. *Tetrahedron Lett.* **1989,30,873-876.** *(0* Wasserman, **H.** H.; Kelly, T. A. *Tetrahedron Lett.* 1989, 30, 7117–7120. (g) Wasserman, H.
H.; Rotello, V. M.; Williams, D. R.; Benbow, J. W. J. Org. Chem. 1989,
54, 2785–2786. (h) Wasserman, H. H.; Ennis, D. S.; Vu, C. B. *Tetrahedron Lett.* **1991,32,6039-6042.**

⁽⁶⁾ Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; Hashimoto, M.; Taga, T. J. Am. Chem. Soc. 1987, 109, 5031.
(7) (a) Sehgal, S. N.; Baker, H.; Vézina, C. J. Antibiot. 1975, 28, 727.

⁽b) Swindells, D. C. N.; **White,** P. S.; Findlay, J. A. *Can.* J. Chem. **1978, 56, 2491.**

⁽⁸⁾ Wasserman, **H. H.; Ennis, D. S.; Rotello, V. M.;** Blum, C. A. *Tetrahedron Lett.* **1992, 33, 6003-6006.**

⁽⁹⁾N-Protected a-amino acids were purchased from the Sigma Chemical Co. **as** either the enantiomerically enriched material or **as** a racemic mixture of enantiomers.

⁽¹⁰⁾ Preliminary results indicate that the BOP ((benzotriazol-lyloxy)tris(dimethylamino)phosphonium hexafluorophosphate) reagent
provides an alternative method for generating the keto ylides in
comparable yields. BOP reagent: (a) Coste, J.; Frerot, E.; Jouin, P.;
Castro, B. Tetrahedro G.; Selve, C.; Seyer, R. *Synthesis* **1977,413.** (c) Castro, **B.;** Dormoy, J. R.; Evin, G.; Selve, C. *Tetrahedron Lett.* **1975,1219-1222.**

we have now prepared the tricarbonyl monohydrates **12- 19** (Table I).

The tricarbonyl derivatives were generally isolated **as** pale green oils, although several samples have crystallized in vacuo. They may be stored at 0 °C for prolonged periods **(>6** months) without observable decomposition. Spectroscopic studies (NMR, IR) confirmed that they exist in the hydrated form. In the IR, peaks at **3600-3300** cm-l are consistent with hydroxyl stretching of the hydrates. In the case of 14 (entry 3, Table I), ¹³C NMR shows a signal at **6 93** ppm, in accord with the known **13C** resonance of related 1,1-diols.¹³ For each of the products, highresolution mass spectrometry **(CI)** gave parent molecular ions in exact agreement with the tricarbonyl forms.14

All of the tricarbonyl monohydrates listed in Table I

(14) Rapid loss of water from the hydrates would be expected under the conditions of chemical ionization maas spectrometry.

Table 11. Peptidyl Tricarbonylr as Inhibitors of HNE, PPE. and α -Chymotrypsin

entry		peptide tricarbonyls	K. HNE (μM)	Kı PPE (μM)	K. α -Chy (μM)
1	12	Z-Ala-Ala-(CO)3-OBn-H ₂ O	0.80	NI	210
2	13	$Z-Gly-He-(CO)3-OBn-H2O$	5.1	NI	1.6
3	14	$Z-Gly-Phe-(CO)3-OBn·H2O$	1.6	NI	0.11
4	15	$Z-Ala-Phe-(CO)3-OBn-H2O$	1.4	30	0.3
5	16	Z-Phe-Glv-(CO) ₃ -OBn-H ₂ O	2.95	47	4.9
6	17	Z-Leu-Ala-(CO)3-OBn-H ₂ O	400	110	6.2
7	18	Z-Ile-Leu-(CO) ₃ -OBn-H ₂ O	959	NI	
8	19	Z-Ile-Gly-Gly-(CO) ₃ -OBn-H ₂ O	0.69	NI	
9	22	\ _N--- (CO) ₃ --- CH ₂ --- NH -- Fmoc+H ₂ O	240	NI	

have now been tested for activity **as** enzyme inhibitors in standard assay procedures^{1c} with the collaboration of Zeneca Pharmaceuticals. The results of these studies are summarized in Table **11.** The compounds were tested against two closely related serine proteases, **HNE** and PPE. Moderately high potency was achieved against **HNE,** and some degree of selectivity between the elastases was demonstrated. Although the same peptides with other electrophilic termini (e.g., TFMK's², α -diketones³, α -keto esters⁴) were not available for comparison, the overall potency of the tricarbonyl compounds appears to be

⁽¹¹⁾ All **of the ylides were fully characterized with elemental analyses, *H NMR, IR, and melting pointa. No epimerization of enantiomerically enriched Cbz-NH-L-Ala,** *[a]=* = **-14.2' (e** = **2, CH&O*H), waa observed during the coupling procedure.** Product **2c** showed a specific rotation, $\lbrack \alpha \rbrack^{21} = +12.45^{\circ}$ (c = 2, CDCl₃), and none of the opposite enantiomer was **detected by1H NMRexperimentaemployingthelanthanideshiftreagent,**

⁽¹²⁾ Waseerman, H. H.; Vu, C. B. Tetrahedron Lett. 1990,31,5205- Eu(fod)s. 5208.

⁽¹³⁾ Jones, T. K.; Reamer, R. A.; Desmond, R.; Mille, S. G. *J. Am.* **Chem. SOC. 1990, ff2,2998-3017.**

Figure 1. Covalent bond-forming reaction between **the peptidyl tricarbonyl substrate and the hydroxyl group of the active site serine leading to formation of the tetrahedral adduct. Scheme I11**

comparable to that observed with these types of inhibitors.16 It is interesting to note that tricarbonyls 14 and 15 (Table 11, entries 3 and **4)** which possess a phenylalanine residue in the P_1 position¹⁶ adjacent to the tricarbonyl array showed potent inhibitory activity toward α -chymotrypsin, an enzyme known to demand a hydrophobic aromatic residue on the carbonyl side of the scissile amide bond.

Serine proteases HNE and PPE differ from α -chymotrypsin in that the binding area is far more extended, and thus, they are more specific for longer chain peptides.' Tripeptidyl tricarbonyl **(19)** (Table 11, entry 8) was the most potent **HNE** inhibitor of **our** synthetic peptido tricarbonyls, in accord with the expected effect of the extended binding site.

By analogy with peptidyl aldehydes, α -keto esters, and TFMK's, we presume that the mechanism for inhibition of serine proteases by the peptidyl tricarbonyls involves formation of a stable hemiketal adduct resulting from attack by the active site serine, either at the central (C_2) carbonyl or at the C_1 carbonyl of the tricarbonyl moiety (Figure 1). In the latter circumstance, the reacting carbonyl might be more favorably positioned relative to the scissile amide bond of the corresponding peptide substrate.

Current work in our laboratories is now directed toward the structural modification of the most active dipeptidyl tricarbonyls in an attempt to improve upon the inhibitory properties. Along the lines of **our** earlier studies related to $FK506^{5g}$ and bicyclomycin,¹⁷ we are also exploring the

coupling of amido ylides (20) with activated carboxylates (21) **as** a route to the generation of a tricarbonyl residue introduced at the N-terminus of a peptide chain (Scheme 11).

In **our** preliminary work in this direction, tricarbonyl22 has been prepared by BSA-mediated coupling^{8,18} of amido phosphoranylidene 23% and N-Fmoc-protected glycyl acid chloride,¹⁹ followed by standard oxidative cleavage (Scheme 111). Product 22 was assayed against several serine proteases and exhibited moderate inhibition of HNE (Table 11, entry 9).

In conclusion, we have shown that peptido carboxylic acids are readily converted into peptidyl tricarbonyls in two mild steps: **(1)** EDCI-promoted coupling with ylide 1 and (2) oxidation.20 Of the tricarbonyl derivatives thus formed, several products exhibit potent inhibition of hydrolytic enzymes.

Acknowledgment. This research was supported by NIH Grant GM 07874. P.L.P. thanks NSERC (Canada) for a postdoctoral fellowship.

Supplementary Material Available: Experimental details and spectroscopic data for all new compounds (7 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and *can* **be ordered from the ACS; see any current masthead page for**

⁽¹⁵⁾ Examples of K_ivalues for related serine protease inhibitors include ordering information. **the following:** (1) Ac-Ala-Phe-CF₃, K_i (α -chymotrypsin) = 11.0 μ M (Brady, K.; Abeles, R. H. *Biochemistry* **1990**, 29, 7608-7617); (2) Ac-Gly-Phe-CF₃, K_i (α -chymotrypsin) = 18 μ M (*Ibid.*); (3) Cbz-Pro-= 1.8 μ M (ref 1d); (4) Cbz-Val-Phe-CO₂Me, K_i (α -chymotrypsin) = 0.06 μ **M** (ref 3a); (5) Boc-D-Phe-Pro-Val-CF₃, K_i (HNE) = 0.16 μ M, K_i (PPE) = 1.8 μ M (ref 4a).

⁽¹⁶⁾ The terminology used **to describe reaidues was originally propoeed** by Schecter and Berger (1967). The amino acid residues of substrates (or inhibitors) are designated P₁, P₂, etc. numbering from the carbonyl of the scissile amide bond in the direction of the amino terminal.

⁽¹⁷⁾ Wasserman, H. H.; Rotello, V. M.; Krause, G. B. Tetrahedron *Lett.* **1992,** *33,* **5414-5422.**

⁽¹⁸⁾ Fmac-glycine, activated by EDCI or BOP, failed to couple with amido phosphoranylidene 20.

⁽¹⁹⁾ Carpino, L. A.; Cohen, B. J.; Stephens, Jr., K. E.; Sadat-Aalaee, S. Y.; Tien, J-H.; Langridge, D. C. *J. Org. Chem.* **1986,52,3732-3734 and references cited therein.**

⁽²⁰⁾ In general, oxidative cleavage *can* **be accomplished more rapidly with ozone; however, Oxone provides a milder and more selective reagent.**